Effect of Osteopathic Manipulative Medicine on Constipation in Parkinson's Disease

Sponsor
New York Institute of Technology (Other)
Overall Status
Recruiting
CT.gov ID
NCT02344485
Collaborator
(none)
20
1
2
96
0.2

Study Details

Study Description

Brief Summary

The aim of this pilot study is to investigate the effect of Osteopathic Manipulative Medicine (OMM) in decreasing constipation symptoms in people with Parkinson's disease (PD). A second but optional aim is to determine if OMM changes the bacterial flora of the mouth and gut. OMM is a safe and gentle manual treatment provided by osteopathic physicians. All participants will receive OMM during the second half of the eleven week trial.

Condition or Disease Intervention/Treatment Phase
  • Procedure: OMM treatment
N/A

Detailed Description

PD is a progressive neurodegenerative disorder which includes motor and non-motor (autonomic) symptoms, such as constipation. OMM has been shown to improve constipation symptoms in non-diseased subjects and cerebral palsy subjects. Constipation will be measured before, during, and after treatment by a constipation scoring system (Cleveland Criteria) to measure the severity of constipation and by the Bristol Stool Scale to measure colonic transit time. The study subjects' assessment of their constipation symptoms (PAC-SYM) and quality of life (PAC-QOL) will also be measured throughout the study.

Studies have also shown that there is a difference in the gut and oral bacterial flora of constipated versus healthy adults, so subjects will be given the option to provide weekly stool samples for analysis to track bacterial colonies and to observe for any flora changes over the study period. This will provide data to determine if bacterial colonies in stool are altered by OMM.

The study will require ten weekly on-site visits over the course of eleven weeks. For the first half of the study, surveys and optional stool tests will be performed without OMM treatment for four weeks to obtain baseline data. For the second half of the study, all subjects will receive OMM for four weeks along with surveys and optional stool microbial tests to obtain the experimental data.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effect of Osteopathic Manipulative Medicine on Constipation in Parkinson's Disease
Study Start Date :
Jan 1, 2015
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: OMM treatment

Subject will receive osteopathic manipulative treatment protocol for constipation in Parkinson's disease once a week for 4 weeks, in addition to continuing with their routine care

Procedure: OMM treatment
OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
Other Names:
  • OMM (Osteopathic Manipulative Medicine)
  • OMT (Osteopathic Manipulative Treatment)
  • Osteopathic manipulation
  • No Intervention: Control

    Subjects will continue with their routine care. No OMM will be performed during this study period

    Outcome Measures

    Primary Outcome Measures

    1. Constipation Scoring System (Cleveland Criteria) [11 week period]

      A standardized form measuring bowel movement patterns will be completed by the subject five times over the study period to see if there is a difference in constipation severity between the period with no OMT and the period with OMT

    Secondary Outcome Measures

    1. Bristol Stool Scale [11 week period]

      A visual standardized stool chart will be used by the subject and study investigator nine times over the study period to visually categorize the shape of the stools to see if there is a difference in colonic transit time between the period with no OMT and the period with OMT

    2. PAC-SYM© [11 week period]

      A standardized form will be completed by the subject five times over the study period to assess constipation symptoms to see if there is a difference between the period with no OMT and the period with OMT

    3. PAC-QOL© [11 week period]

      A standardized form will be completed by the subject five times over the study period to assess the impact of constipation on daily life to see if there is a difference between the period with no OMT and the period with OMT

    Other Outcome Measures

    1. Stool analysis [11 week period]

      Subjects will have the option of submitting stool samples up to five times over the study period to see if there is a difference in the gut bacterial flora between the period with no OMT and the period with OMT

    2. Mouth analysis [11 week period]

      Subjects will have the option of submitting mouth samples (ie. cheek swabs) up to five times over the study period to see if there is a difference in the oral bacterial flora between the period with no OMT and the period with OMT

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Medically diagnosed with Parkinson's disease

    • Medically diagnosed with constipation (according to Rome III criteria)

    • Be over 40 years old

    Exclusion Criteria:
    • No diagnosis of Parkinson's disease

    • No diagnosis of constipation that satisfies Rome III criteria

    • Medically diagnosed with irritable bowel syndrome

    • Another diagnosed cause for chronic constipation

    • Currently pregnant

    • Have another diagnosed neurologic condition (excluding headache or migraine, headache, migraine, dysautonomia, depression or other mood disorders (unless severe or uncontrolled), dementia or cognitive changes (unless severe), diffuse lewy body dementia, REM sleep behavior disorder, normal pressure hydrocephalus, multiple system atrophy P and C types, progressive supranuclear palsy, vascular parkinsonism, corticobasal ganglionic degeneration, and drug induced parkinsonism)

    • Spinal cord abnormality or lesion

    • Cancer of the gastrointestinal tract, abdomen, or pelvis

    • Anemia that has not been evaluated

    • Unexplained weight loss, fever, night sweats, rectal bleeding, or black stools in past 2 months

    • Active hepatitis, infectious mononucleosis, or enlarged spleen

    • Abdominal aortic aneurysm

    • Congenital malformation of the gastrointestinal tract

    • Abdominal or pelvic surgery within the past 6 weeks

    • Unable or unwilling to receive OMT.

    • Unable or unwilling to rate one's own stools using a visual chart or to bring a picture of one's stool to each visit

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 New York Institute of Technology- Academic Health Care Center Old Westbury New York United States 11568

    Sponsors and Collaborators

    • New York Institute of Technology

    Investigators

    • Principal Investigator: Jayme Mancini, D.O., New York Institute of Technology- Academic Health Care Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    New York Institute of Technology
    ClinicalTrials.gov Identifier:
    NCT02344485
    Other Study ID Numbers:
    • BHS-1065
    First Posted:
    Jan 26, 2015
    Last Update Posted:
    Nov 5, 2021
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 5, 2021